Human Genome Sciences (HGSI)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

 
Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Aug 8, 2012)
  • 8-K (Aug 1, 2012)
  • 8-K (Jul 16, 2012)
  • 8-K (May 17, 2012)
  • 8-K (May 16, 2012)
  • 8-K (Apr 24, 2012)

 
Other

Human Genome Sciences 8-K 2012

Documents found in this filing:

  1. 8-K
  2. Ex-99.1
  3. Ex-99.2
  4. Graphic
  5. Graphic
  6. Graphic
  7. Graphic
  8. Graphic
  9. Graphic
  10. Graphic
  11. Graphic
  12. Graphic
  13. Graphic
  14. Graphic
  15. Graphic
  16. Graphic
  17. Graphic
  18. Graphic
  19. Graphic
  20. Graphic
  21. Graphic
  22. Graphic
  23. Graphic
  24. Graphic
  25. Graphic
  26. Graphic
  27. Graphic
  28. Graphic
  29. Graphic
  30. Graphic
  31. Graphic
  32. Graphic
  33. Graphic
  34. Graphic
Form 8-K
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 9, 2012
HUMAN GENOME SCIENCES, INC.
(Exact name of registrant as specified in its charter)
         
Delaware   001-14169   22-3178468
         
(State or other jurisdiction
of incorporation) 		  (Commission File Number)   (IRS Employer Identification No.)
     
14200 Shady Grove Road,
Rockville, Maryland 		   
20850-7464
     
(Address of principal executive offices)   (Zip Code)
Registrant’s telephone number, including area code: (301) 309-8504
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

Item 2.02. Results of Operations and Financial Condition.
On January 9, 2012, the Company issued the press release attached as Exhibit 99.1 to this Form 8-K, which includes BENLYSTA® sales figures for 2011, guidance regarding cash and investments at year-end 2011 and SG&A and R&D expense for both 2011 and 2012, a business update, and the Company’s priority goals for 2012. In addition, certain information relating to weekly gross sales of BENLYSTA and financial guidance are included in Exhibit 99.2, which is incorporated by reference into this Item 2.02.
Item 7.01. Regulation FD Disclosure.
During the week of January 9, 2012, representatives of Human Genome Sciences, Inc. will be attending meetings with investors, analysts and others at the JP Morgan Healthcare Conference in San Francisco, California, and will be presenting at the conference on Monday, January 9, 2012, at 4:30 p.m. Pacific time (7:30 p.m. Eastern time). During these meetings and the presentation and from time to time, the Company will present the slides attached as Exhibit 99.2 to this Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
         
  99.1    
Press Release, dated January 9, 2012
  99.2    
Slide Presentation, dated January 9, 2012

 

 

 

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  HUMAN GENOME SCIENCES, INC.
 		  
  By:   /s/ James H. Davis, Ph.D.    
    Name:   James H. Davis, Ph.D.   
    Title:   Executive Vice President, General Counsel and Secretary   
Date: January 9, 2012

 

 

 

INDEX TO EXHIBITS
         
Exhibit No.   Description
 
  99.1    
Press Release, dated January 9, 2012
  99.2    
Slide Presentation, dated January 9, 2012

 

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki